Our previous studies demonstrated that exogenous AAT injection increased the antioxidants and suppresses oxidative stress, and subsequent prevention of preeclampsia development through inhibiting STAT1/ p38MAPK signaling [18, 19], suggesting that AAT would become a potential strategy for preeclampsia therapy. The gene discussed is STAT1; the disease is preeclampsia.